Paul Kirschmeier

Paul Kirschmeier

UNVERIFIED PROFILE

Are you Paul Kirschmeier?   Register this Author

Register author
Paul Kirschmeier

Paul Kirschmeier

Publications by authors named "Paul Kirschmeier"

Are you Paul Kirschmeier?   Register this Author

57Publications

1721Reads

9Profile Views

Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Cancer Discov 2018 02 3;8(2):196-215. Epub 2017 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809290PMC
February 2018

New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.

Bioorg Med Chem Lett 2014 Feb 2;24(4):1228-31. Epub 2014 Jan 2.

Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2013.12.046DOI Listing
February 2014

Discovery of C-imidazole azaheptapyridine FPT inhibitors.

Bioorg Med Chem Lett 2010 Feb 6;20(3):1134-6. Epub 2009 Dec 6.

Schering Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.12.013DOI Listing
February 2010

Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.

Bioorg Med Chem Lett 2010 Feb 7;20(4):1384-7. Epub 2010 Jan 7.

Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.01.007DOI Listing
February 2010

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.

Int J Cancer 2009 Dec;125(11):2711-20

Schering-Plough Research Institute, Biological Research - Oncology, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.24644DOI Listing
December 2009

Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.

J Biol Chem 2008 Sep 9;283(37):25150-63. Epub 2008 Jul 9.

Lineberger Comprehensive Cancer Center, Division of Pharmacotherapy and Experimental Therapeutics, Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M800882200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533093PMC
September 2008

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

Gynecol Oncol 2008 Apr 31;109(1):97-106. Epub 2008 Jan 31.

Schering-Plough Research Institute, Biological Research-Oncology, 2015 Galloping Hill Road, K15-2-2700, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2007.12.013DOI Listing
April 2008

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).

Anticancer Drugs 2007 Sep;18(8):923-31

Department of Biological Research - Oncology, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e3280c1416eDOI Listing
September 2007

AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines.

Cancer Biol Ther 2007 May 9;6(5):755-62. Epub 2007 Feb 9.

Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.6.5.3995DOI Listing
May 2007

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors.

Cancer Biol Ther 2006 Apr 19;5(4):419-26. Epub 2006 Apr 19.

DNAX Research Institute, Schering-Plough Research Institute, Kenilworth, New Jersey 07333, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.4.2521DOI Listing
April 2006

Lipid posttranslational modifications. Farnesyl transferase inhibitors.

J Lipid Res 2006 Jan 8;47(1):15-31. Epub 2005 Nov 8.

Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1194/jlr.R500012-JLR200DOI Listing
January 2006

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.

J Biol Chem 2005 Sep 8;280(35):31101-8. Epub 2005 Jul 8.

Department of Tumor Biology, Schering-Plough Research Institute, Kenilwort, New Jersey 07033, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M503763200
Publisher Site
http://dx.doi.org/10.1074/jbc.M503763200DOI Listing
September 2005

Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.

Bioorg Med Chem Lett 2004 Dec;14(23):5877-80

Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-3-3545, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2004.09.026DOI Listing
December 2004

Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.

Bioorg Med Chem Lett 2004 Dec;14(23):5899-902

Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-3-3545, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2004.09.020DOI Listing
December 2004

Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

Curr Opin Drug Discov Devel 2004 Jul;7(4):478-86

Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-1300, USA.

View Article

Download full-text PDF

Source
July 2004

Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation.

Cancer Biol Ther 2003 Jul-Aug;2(4 Suppl 1):S96-104

Department of Biological Research-Oncology, Shering Plough Research Institute, Kenilworth, New Jersey 07033, USA.

View Article

Download full-text PDF

Source
February 2004

Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.

Curr Top Med Chem 2003 ;3(10):1103-14

Department of Medicinal Chemistry, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026033452104DOI Listing
June 2003

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.

Oncogene 2003 Jun;22(23):3645-54

Tumor Biology Department, Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-4 (4600), Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206477DOI Listing
June 2003

Preclinical and clinical evaluation of farnesyltransferase inhibitors.

Curr Oncol Rep 2003 Mar;5(2):99-107

Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-3-3200, Kenilworth, NJ 07033-1300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-003-0096-5DOI Listing
March 2003

Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells.

J Biol Chem 2002 Sep 22;277(39):36329-37. Epub 2002 Jul 22.

Tumor Biology Department, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M204962200DOI Listing
September 2002

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.

Oncogene 2002 Apr;21(17):2613-22

Tumor Biology Department, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1205353DOI Listing
April 2002

Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.

Exp Cell Res 2002 Feb;273(2):138-46

Biotechnology Development, Schering-Plough Research Institute, Union, New Jersey 07083, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/excr.2001.5440DOI Listing
February 2002